NCT06506955 2026-03-11
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
Clinical Trials
6 trialsNCT02807181 2025-05-09
SIRCCA
Sirtex Medical
Phase 2/3 Terminated
NCT05506943 2025-04-20
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Compass Therapeutics
Phase 2/3 Active not recruiting
NCT04066491 2023-11-14
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono
Phase 2/3 Terminated
NCT05429697 2022-09-27
Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
SMT bio Co., Ltd.
Phase 2/3 Recruiting
NCT03086993 2022-03-24
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
Delcath Systems Inc.
Phase 2/3 Unknown